Compass Therapeutics ( ($CMPX) ) has issued an update. On January 6, 2026, Compass Therapeutics reported an estimated, unaudited cash and ...

The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaborati ...

Thousands have reclaimed health through this structured path, and Marchman Act Addiction Treatment stands as one respected guide in the field ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Alumis: Top-line ...

A unified digital guide simplifying coastal tourism procedures and providing clear pathways for yachting activities across the Saudi Red Sea. The first series of the guide provides a clear, end-to-end ...

On December 17, Gavin Clark-Gartner, an analyst at Evercore ISI, reaffirmed a ‘Hold’ rating on COMPASS Pathways plc ...

Maryland unveils Community Business Compass with data tools and $10M in funding to boost child care and fresh food access.

With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at ...

COMPASS Pathways plc misses on earnings expectations. Reported EPS is $-1.44451 EPS, expectations were $-0.4. Operator: Good morning, ladies and gentlemen, and thank you for standing by. My name is ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third ...